Neil M. Frazer
Keine laufenden Positionen mehr
Profil
Neil M.
Frazer is the founder of DMK Pharmaceuticals Corp.
(Old).
He worked as a Chief Medical Officer at Chimerix, Inc. and OncoSil Medical Ltd.
He also served as a Non-Executive Director & Chief Medical Officer at Immutep Ltd.
Mr. Frazer completed his undergraduate degree at The University of Edinburgh.
Ehemalige bekannte Positionen von Neil M. Frazer
Unternehmen | Position | Ende |
---|---|---|
ONCOSIL MEDICAL LIMITED | Vorstandsvorsitzender | 09.09.2014 |
DMK Pharmaceuticals Corp. (Old)
DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Gründer | - |
IMMUTEP LIMITED | Technik-/Wissenschafts-/F&E-Leiter | - |
CHIMERIX, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Neil M. Frazer
The University of Edinburgh | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
CHIMERIX, INC. | Health Technology |
IMMUTEP LIMITED | Health Technology |
ONCOSIL MEDICAL LIMITED | Health Technology |
Private Unternehmen | 1 |
---|---|
DMK Pharmaceuticals Corp. (Old)
DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Health Technology |